Seeking Alpha

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

-Interim results from Phase II AAVIATE and ALTITUDE trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation -Initial safety ...

Medera Receives FDA Fast Track Designation for Gene Therapy Targeting Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, and its clinical development division Sardocor, today announced that the U.S.
Business Wire

Forge Biologics Selected as an AAV Manufacturing Partner for California Institute for Regenerative Medicine to Help Accelerate Gene Therapy Programs

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today that it has joined the California Institute for Regenerative Medicine’s (CIRM) ...

VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a ...

Andelyn Biosciences Partners with Evolyra Therapeutics for the Clinical Manufacturing of Gene Therapies for the Treatment of Limb-Girdle Muscular Dystrophies

Andelyn Biosciences, a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), announced today a partnership with Evolyra Therapeutics to ...
Seeking Alpha

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its ...

Virica Biotech and FUJIFILM Biosciences Collaborate Under the Canada--Japan Co--Innovation Program to Advance AAV Production Enhancers

Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs. -- Virica and ...
Business Insider

Amicus Therapeutics Acquires Gene Therapy Portfolio of Ten Clinical and Pre-Clinical Stage AAV Programs in Neurologic Lysosomal Storage Disorders

License with Nationwide Children’s Hospital (NCH) through the Acquisition of Celenex (NCH Spinout) Establishes Amicus as Leading Gene Therapy Company in Neurologic Lysosomal Storage Disorders (LSD) ...
Business Wire

Affinia Therapeutics Presents New Data on its Lead AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the ...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies ...
Nasdaq

Abeona Therapeutics Announces Update on AAV Ophthalmology Program

NEW YORK and CLEVELAND, March 14, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced three internally developed investigational preclinical gene therapy product ...

VectorBuilder Introduces High-Stability MuteFree AAV to Improve Gene Therapy Manufacturing Reliability

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in ge ...